TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2020

Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial.

Junjie Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.